HCPCS Code J1655: Injection, tinzaparin sodium, 1000 IU

Key takeaways

HCPCS Code J1655 covered injection of tinzaparin sodium, 1,000 IU per billed unit.

J1655 has been deleted from the active HCPCS Level II code set, so a current claim auto-rejects.

Tinzaparin administrations now route to a crosswalk code, typically the unlisted drug code J3490.

Medicare paid J1655 under the Average Sales Price method, which CMS updates every quarter.

Every claim still needs the NDC, an accurate unit count, and an ICD-10 code that supports medical necessity.

HCPCS Code J1655 is a Level II J-code for injection of tinzaparin sodium, 1,000 IU per billed unit. Tinzaparin sodium is a low molecular weight heparin (LMWH) used to treat and prevent deep vein thrombosis and pulmonary embolism.

J1655 is no longer active. It has been deleted from the HCPCS Level II code set, so a current claim under this code rejects automatically.

This reference covers the official descriptor, the deletion, and what to bill instead. It also walks through unit calculation, NDC reporting, Medicare’s ASP payment method, and the ICD-10 codes that support medical necessity.

HCPCS Code J1655: Definition and official descriptor

HCPCS Code J1655 falls within the J-code subset of HCPCS Level II, the coding system CMS maintains for products and services outside CPT. J-codes cover drugs a healthcare professional administers, rather than drugs the patient takes at home. They are the standard route for billing Medicare and Medicaid for outpatient injectable drugs.

The official descriptor is: Injection, tinzaparin sodium, 1000 IU. Each billed unit represents 1,000 international units delivered by injection. J1655 sat in the anticoagulant injectable group alongside enoxaparin, fondaparinux, and unfractionated heparin.

Tinzaparin sodium: Drug overview and clinical indications

Tinzaparin sodium is a low molecular weight heparin, produced by controlled depolymerization of unfractionated heparin. It binds antithrombin III to inhibit Factor Xa, and to a lesser degree thrombin.

That interrupts the coagulation cascade. Compared with unfractionated heparin, LMWHs give more predictable pharmacokinetics and usually need less laboratory monitoring.

The FDA-approved indications center on thromboembolic conditions. Before you link J1655 to a diagnosis, confirm the indication matches the drug’s approved labeling. Check the treating MAC’s local coverage determination (LCD) too, since coverage varies by payer.

• Deep vein thrombosis (DVT): treatment of acute DVT in adults, with or without pulmonary embolism
• Pulmonary embolism (PE): anticoagulation in confirmed PE where tinzaparin is clinically indicated
• DVT prophylaxis: prevention in surgical patients, particularly orthopedic cases (confirm MAC coverage)
• Extended anticoagulation: bridge therapy for patients who need sustained anticoagulation

Understanding the clinical picture behind a J-code claim strengthens medical necessity documentation. The diagnosis on the claim has to explain why this drug was given, on this date, to this patient.

Is J1655 still active?

No. J1655 has been removed from the active HCPCS Level II code set, and AAPC’s code database lists it under a deleted code path. CMS publishes HCPCS Level II updates each fall, with changes taking effect on January 1.

Tinzaparin’s small US commercial footprint likely contributed to the removal. Innohep, the branded product, ran into distribution problems in the US market.

What this means for billing teams: a deleted code submitted to Medicare or Medicaid rejects automatically. Before billing any tinzaparin administration, work through these four steps.

1. Confirm the deletion date in the CMS HCPCS Level II code files for the applicable service year
2. Check whether CMS published a crosswalk code or pointed billers to an unlisted drug code such as J3490 or J3590
3. Read the relevant MAC’s billing and coding article for anticoagulant injectable claims
4. Flag J1655 as inactive in your practice management system, and route tinzaparin claims to the correct current code

Practices using digital clinical forms that auto-populate billing codes can set an alert for retired codes. The claim draft gets flagged before submission, not after the denial arrives.

How to bill J1655: Coding and documentation requirements

When J1655 was active, billing followed the standard J-code framework for outpatient injectable drugs under Medicare Part B. Those requirements still matter. Billing teams audit historical claims and handle appeals for services rendered while the code was live.

Unit calculation

Each billed unit of J1655 equals 1,000 IU of tinzaparin sodium. A patient who received 18,000 IU in one administration generates 18 units on the claim. Over-reporting or under-reporting units is a common audit finding and a frequent trigger for recoupment.

Unit definitions differ from drug to drug, so read each descriptor before you calculate. J1250 is billed per 250 mg, not per IU.

National Drug Code (NDC) reporting

Medicare requires NDC information on most drug claims submitted under J-codes. The NDC must reflect the product actually administered, not a generic equivalent. Claims missing the N4 qualifier, the NDC number, or the quantity reject under most MAC edits.

Confirm the exact NDC format with your MAC’s billing and coding article for anticoagulant injectables. The same discipline applies to biologics such as J0885. A complete record of administered NDCs supports HIPAA-compliant documentation and defends the claim at audit.

Place of service and site-of-service adjustments

Reimbursement rates for J-codes differ by site of service. Hospital outpatient departments bill under the Outpatient Prospective Payment System (OPPS). Physician office settings bill under the Medicare Physician Fee Schedule (MPFS).

In the hospital outpatient setting, drug payments usually run through packaged payment or the OPPS packaging threshold. The separate ASP-based rate applies in office settings instead.

Modifier use

J-code drug claims need no special modifiers beyond the standard set. That includes GY for items Medicare does not cover, plus JW or JZ for drug wastage. Wastage reporting matters most with single-dose vials, as it does on J1441 claims. Confirm modifier requirements against the applicable MAC’s local coverage policies.

Medicare reimbursement for J1655

Medicare paid J1655 under the Average Sales Price (ASP) methodology, the standard mechanism for separately payable Part B drugs. CMS updates ASP payment limits quarterly, in January, April, July, and October. Any historical rate lookup has to reference the correct quarter’s ASP file.

Under ASP methodology, Medicare pays ASP plus 6% for most Part B drugs in physician office settings. Hospital outpatient settings use OPPS rates, which may differ.

Because J1655 is deleted, current ASP files carry no payment rate for it. The CMS Physician Fee Schedule lookup tool confirms whether a successor code carries its own ASP rate.

ICD-10 diagnosis codes used with J1655

Medical necessity for a tinzaparin claim rests on an ICD-10 code that matches the drug’s FDA-approved indications. The treating MAC’s LCD decides which pairings it will accept. The table below covers the pairings that come up most often.

Coverage for DVT prophylaxis varies widely by MAC, so confirm the applicable LCD before you submit a prophylaxis claim. One rule holds across every payer. The primary diagnosis must support the drug’s approved indication.

Related HCPCS codes for anticoagulant injections

When J1655 is unavailable, billing teams need the correct active code for the anticoagulant actually administered. The table below covers the low molecular weight heparin and related anticoagulant J-codes billed most often.

Enoxaparin sodium (J1650) is the most frequently billed LMWH J-code in the US, thanks to wide availability and settled Medicare coverage. If the prescriber switches a patient from tinzaparin to enoxaparin, the claim moves to J1650 with units recalculated per 10 mg. Unfractionated heparin claims run through J1644 instead.

Common billing errors and denial reasons

Denials on J1655 and related anticoagulant J-codes cluster around a short list of errors. Catching them before submission is faster than working the appeal cycle. It also keeps the revenue cycle predictable.

• Submitting a deleted code: any J1655 claim dated after the deletion takes effect will auto-reject. Verify code status against the CMS annual HCPCS update for the service year.
• Wrong unit count: billing 1 unit for an 18,000 IU dose is the most common unit error. Recalculate units from the administered dose every time.
• Missing or malformed NDC: claims reject under standard MAC edits without the N4 qualifier, an 11-digit NDC, and the correct unit of measure.
• Diagnosis code mismatch: a diagnosis that does not map to tinzaparin’s approved indications fails medical necessity review. Confirm the ICD-10 pairing against the applicable LCD first.
• Unlisted code without documentation: J3490 claims need an invoice and a drug description attached, as the MAC requires. Missing paperwork sends them straight to medical review.
• Site-of-service error: billing physician office rates for a drug given in a hospital outpatient setting invites recoupment. Confirm the place of service code before submission.

How Pabau keeps injectable drug claims clean

In many practices, injectable drug detail lives in three places at once. The dose sits in the treatment note, the NDC on a vial label or spreadsheet, and the code in the charge master. When one drifts out of step, the claim denies.

Practice management software like Pabau keeps those three together. Pabau’s claims management software pulls the administered product, the dose, and the code from the same clinical record. Your biller sees what the clinician charted, so the unit count on the claim matches the note.

That matters most in practices that inject every day. IV therapy practices and men’s health practices bill drug codes on almost every visit. One mis-set unit definition then repeats across hundreds of claims.

Structured records also make the annual charge master review quick. You can see which codes you billed and when, then check that list against the current CMS update file before January’s changes bite.

Keep injectable drug claims accurate

Pabau links the administered product, dose, and NDC to the clinical record, so your billing team codes from what the clinician actually charted. Fewer unit errors, fewer denials to work.

Book a demo

Conclusion

Treat J1655 as a historical code. Anything you bill today for tinzaparin goes out under a crosswalk code, most often J3490, with an invoice and a drug description attached.

The larger lesson sits in the charge master rather than in this one code. HCPCS deletions land every January, and a code that paid in December can reject in February. A yearly review takes an afternoon. Working the denials it would have prevented takes far longer.

Book a demo to see how Pabau keeps injectable drug documentation and claim codes in step across every service date.

Continue your research

Billing another unit-based Part B injectable? J1120 covers acetazolamide sodium injection, from unit calculation through to NDC reporting.

Need the deferoxamine mesylate code? J0895 is billed per 500 mg and follows the same J-code documentation rules.

Coding an antiemetic injection? J0780 covers prochlorperazine, a high-volume outpatient drug claim in most specialties.

Billing an intravenous antibiotic? J1364 covers erythromycin lactobionate and the documentation Medicare expects with it.

Working a chelation therapy claim? J0600 covers edetate calcium disodium, another Part B injectable billed by unit.

Frequently asked questions